Cyclerion Therapeutics Statistics
Total Valuation
CYCN has a market cap or net worth of $8.25 million. The enterprise value is $4.15 million.
Important Dates
The next estimated earnings date is Friday, May 16, 2025, after market close.
| Earnings Date | May 16, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CYCN has 2.55 million shares outstanding. The number of shares has increased by 4.80% in one year.
| Current Share Class | 2.55M |
| Shares Outstanding | 2.55M |
| Shares Change (YoY) | +4.80% |
| Shares Change (QoQ) | +0.55% |
| Owned by Insiders (%) | 27.69% |
| Owned by Institutions (%) | 13.76% |
| Float | 1.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.99 |
| Forward PS | n/a |
| PB Ratio | 1.14 |
| P/TBV Ratio | 0.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.99 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.21
| Current Ratio | 4.21 |
| Quick Ratio | 3.96 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -31.48% and return on invested capital (ROIC) is -23.17%.
| Return on Equity (ROE) | -31.48% |
| Return on Assets (ROA) | -20.43% |
| Return on Invested Capital (ROIC) | -23.17% |
| Return on Capital Employed (ROCE) | -39.49% |
| Revenue Per Employee | $2.08M |
| Profits Per Employee | -$2.94M |
| Employee Count | 1 |
| Asset Turnover | 0.20 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.86% in the last 52 weeks. The beta is 1.67, so CYCN's price volatility has been higher than the market average.
| Beta (5Y) | 1.67 |
| 52-Week Price Change | +2.86% |
| 50-Day Moving Average | 2.79 |
| 200-Day Moving Average | 2.90 |
| Relative Strength Index (RSI) | 55.07 |
| Average Volume (20 Days) | 16,798 |
Short Selling Information
The latest short interest is 52,070, so 2.05% of the outstanding shares have been sold short.
| Short Interest | 52,070 |
| Short Previous Month | 45,669 |
| Short % of Shares Out | 2.05% |
| Short % of Float | 3.11% |
| Short Ratio (days to cover) | 3.46 |
Income Statement
In the last 12 months, CYCN had revenue of $2.08 million and -$2.94 million in losses. Loss per share was -$1.16.
| Revenue | 2.08M |
| Gross Profit | 2.08M |
| Operating Income | -3.47M |
| Pretax Income | 3.01M |
| Net Income | -2.94M |
| EBITDA | n/a |
| EBIT | -3.47M |
| Loss Per Share | -$1.16 |
Full Income StatementBalance Sheet
The company has $3.64 million in cash and n/a in debt, giving a net cash position of $3.64 million or $1.43 per share.
| Cash & Cash Equivalents | 3.64M |
| Total Debt | n/a |
| Net Cash | 3.64M |
| Net Cash Per Share | $1.43 |
| Equity (Book Value) | 8.78M |
| Book Value Per Share | 2.87 |
| Working Capital | 3.43M |
Full Balance SheetCash Flow
| Operating Cash Flow | -3.43M |
| Capital Expenditures | n/a |
| Free Cash Flow | -3.43M |
| FCF Per Share | -$1.35 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -166.60% and -141.47%.
| Gross Margin | 100.00% |
| Operating Margin | -166.60% |
| Pretax Margin | -141.47% |
| Profit Margin | -141.47% |
| EBITDA Margin | n/a |
| EBIT Margin | -166.60% |
| FCF Margin | n/a |